ELASTASA FECAL-1 (EF-1) COMO DIAGNÓSTICO DE INSUFICIENCIA PANCREÁTICA EXÓCRINA EN PACIENTES CON DIABETES MELLITUS, DEL HOSPITAL “DR. TEODORO MALDONADO CARBO”, SEPTIEMBRE-DICIEMBRE 2018

Abstract

The Exocrine Pancreatic Insufficiency (IPE) is a very common pathology in the Gastroenterology and Endocrinology consultations, however, in recent years, it has been a little forgotten by a part of the medical staff. Early detection with the use of the Elastase Fecal-1 test in patients who already have affected the gland is important. Objective: To determine the utility of Elastase Fecal-1 in the diagnosis of Exocrine Pancreatic Insufficiency in patients with Diabetes Mellitus type I and II (DM). Methodology: Experimental, prospective, descriptive and cross-sectional study that included 60 patients diagnosed with Diabetes Mellitus type I and II of the endocrinology outpatient clinic of the "Teodoro Maldonado Carbo" Specialties Hospital, from the period of September 1 to on December 31, 2018. For the commercial kit test (human pancreatic elastase ELISA BS 86-01) and for data analysis the Microsoft Excel 2010 spreadsheet was used. Results: The patients older than 60 years prevailed with 53.3% (32 \ 60) and with greater frequency of the feminine sex 51.7% (31 \ 60). On the other hand, the frequency of IPE in patients with DM of the study was 38.3%. The average value of fecal Elastase-1 was 212.73 ug / g feces. 73.9% (40 \ 60) of patients with pancreatic insufficiency had more than 10 years of evolution of diabetes and of that group 56.5% corresponded to the female sex. Conclusions: The frequency of PEI prevailed in patients with DM with more than 10 years of evolution and predominance of women older than 60 years.